See more : XRApplied Technologies Inc. (XRAPF) Income Statement Analysis – Financial Results
Complete financial analysis of Golden Biotechnology Corporation (4132.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Golden Biotechnology Corporation, a leading company in the None industry within the None sector.
You may be interested
- Silgan Holdings Inc. (SLGN) Income Statement Analysis – Financial Results
- Dar Almarkabah for Renting Cars Co. (9577.SR) Income Statement Analysis – Financial Results
- Beijing UniStrong Science&Technology CO.,LTD (002383.SZ) Income Statement Analysis – Financial Results
- Oie Sangyo Co., Ltd. (7481.T) Income Statement Analysis – Financial Results
- Vimeo, Inc. (VMEO) Income Statement Analysis – Financial Results
Golden Biotechnology Corporation (4132.TWO)
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 63.43M | 217.83M | 81.77M | 88.83M | 83.29M |
| Cost of Revenue | 47.37M | 66.03M | 69.08M | 64.17M | 38.43M |
| Gross Profit | 16.06M | 151.79M | 12.69M | 24.66M | 44.87M |
| Gross Profit Ratio | 25.31% | 69.69% | 15.51% | 27.76% | 53.87% |
| Research & Development | 202.52M | 278.42M | 265.10M | 194.77M | 142.12M |
| General & Administrative | 160.64M | 152.88M | 161.17M | 156.74M | 131.93M |
| Selling & Marketing | 18.48M | 17.26M | 10.27M | 21.19M | 41.62M |
| SG&A | 179.12M | 170.14M | 171.43M | 177.93M | 173.21M |
| Other Expenses | 0.00 | 24.76M | -14.32M | -37.02M | 0.00 |
| Operating Expenses | 381.64M | 448.56M | 436.53M | 372.70M | 325.81M |
| Cost & Expenses | 429.01M | 514.59M | 505.61M | 436.86M | 364.23M |
| Interest Income | 8.81M | 4.33M | 326.00K | 279.00K | 217.00K |
| Interest Expense | 6.73M | 4.08M | 3.69M | 4.14M | 4.24M |
| Depreciation & Amortization | 51.03M | 51.20M | 51.18M | 56.91M | 46.11M |
| EBITDA | -303.59M | -216.48M | -386.66M | -327.77M | -214.72M |
| EBITDA Ratio | -478.63% | -99.38% | -472.87% | -369.12% | -269.34% |
| Operating Income | -365.58M | -267.69M | -437.84M | -384.78M | -270.46M |
| Operating Income Ratio | -576.36% | -122.89% | -535.47% | -433.19% | -324.71% |
| Total Other Income/Expenses | 4.23M | 25.01M | -17.69M | -40.78M | -14.51M |
| Income Before Tax | -361.35M | -271.76M | -441.53M | -388.82M | -284.97M |
| Income Before Tax Ratio | -569.69% | -124.76% | -539.98% | -437.74% | -342.13% |
| Income Tax Expense | 293.00K | 116.00K | 2.30M | 2.55M | 157.00K |
| Net Income | -361.64M | -271.88M | -443.84M | -391.38M | -285.12M |
| Net Income Ratio | -570.15% | -124.81% | -542.80% | -440.61% | -342.31% |
| EPS | -2.54 | -1.91 | -3.36 | -3.49 | -2.43 |
| EPS Diluted | -2.54 | -1.91 | -3.36 | -3.11 | -2.48 |
| Weighted Avg Shares Out | 142.23M | 142.23M | 132.23M | 112.23M | 117.56M |
| Weighted Avg Shares Out (Dil) | 142.38M | 142.23M | 132.23M | 125.69M | 114.97M |
No news found for: 4132.TWO
Source: https://incomestatements.info
Category: Stock Reports